Cargando…
Risk of infections of biological and targeted drugs in patients with spondyloarthritis: meta-analysis of randomized clinical trials
BACKGROUND: Concerns exist regarding the risk of infections in patients with spondyloarthritis (SpA) treated with biologics. We assessed the risk of infections of biological and targeted drugs in patients with SpA by performing a meta-analysis based on randomized controlled trials (RCTs). METHODS: A...
Autores principales: | Hu, Lidong, Man, Siliang, Ji, Xiaojian, Wang, Yiwen, Liu, Xingkang, Zhang, Jiaxin, Song, Chuan, Zhu, Jian, Huang, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276457/ https://www.ncbi.nlm.nih.gov/pubmed/35730370 http://dx.doi.org/10.1097/CM9.0000000000001928 |
Ejemplares similares
-
Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials
por: Ji, Xiaojian, et al.
Publicado: (2022) -
Risk of Malignancy and Tuberculosis of Biological and Targeted Drug in Patients With Spondyloarthritis: Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Man, Siliang, et al.
Publicado: (2021) -
Risk of malignancies in patients with spondyloarthritis treated with biologics compared with those treated with non-biologics: a systematic review and meta-analysis
por: Kwan, Yu Heng, et al.
Publicado: (2020) -
Underweight and obesity are strong predictors of clinical outcomes in
patients with ankylosing spondylitis: data from the Smart-phone
SpondyloArthritis Management System
por: Hu, Lidong, et al.
Publicado: (2021) -
Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials
por: Persson, Monica S M, et al.
Publicado: (2018)